Ignite Creation Date:
2025-12-25 @ 4:01 AM
Ignite Modification Date:
2025-12-26 @ 2:54 AM
Study NCT ID:
NCT04723602
Status:
COMPLETED
Last Update Posted:
2022-08-03
First Post:
2020-12-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Sponsor:
Albert B. Sabin Vaccine Institute
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Body mass index | View |
| None | Coronavirus Disease | View |
| None | Creatine phosphokinase | View |
| None | Clinical Research Associate | View |
| None | Contract Research Organization | View |
| None | Division of AIDS | View |
| None | Disseminated Intravascular Coagulation | View |
| None | Diagnostic Lab of Oklahoma | View |
| None | Deoxyribonucleic Acid | View |
| None | Species Zaire Ebolavirus | View |
| None | Electronic Case Report Form | View |
| None | Ethylenediaminetetraacetic Acid | View |
| None | Ebola Hemorrhagic Fever | View |
| None | Enzyme-Linked Immunosorbent Assay | View |
| None | Food and Drug Administration | View |
| None | Ebola Virus Disease | View |
| None | Degrees Fahrenheit | View |
| None | Good Clinical Practices | View |
| None | Good Laboratory Practices | View |
| None | Grams | View |
| None | Glycoprotein | View |
| None | Government and Public Health Solutions | View |
| None | GlaxoSmithKline | View |
| None | Hemagglutinin | View |
| None | Hereditary Angioedema | View |
| None | Hepatitis B Virus | View |
| None | Hepatitis C Virus | View |
| None | Human immunodeficiency virus | View |
| None | Human T-cell Leukemia Lymphoma Virus | View |
| None | Investigator's Brochure | View |
| None | International Council for Harmonisation | View |
| None | International Committee on the Taxonomy of Viruses | View |
| None | Identification | View |
| None | Immunoglobulin G | View |
| None | Immunoglobulin M | View |
| None | Intramuscular(ly) | View |
| None | Investigational New Drug | View |
| None | Investigational product | View |
| None | Intravenous | View |
| None | Marburg Virus | View |
| None | Marburg Virus Disease | View |
| None | Marburg hemorrhagic fever | View |
| None | Milliliter | View |
| None | Millimeters of Mercury | View |
| None | Modified Vaccinia Ankara | View |
| None | Nucleic Acid Test | View |
| None | Non-Disclosure Agreement | View |
| None | Non-Human Primate | View |
| None | National Institute of Allergy and Infectious Diseases | View |
| None | National Institutes of Health | View |
| None | Nucleoprotein | View |
| None | Nonsteroidal Anti-Inflammatory Drug | View |
| None | Oklahoma Blood Institute | View |
| None | Office for Human Research Protection | View |
| None | Plasmapheresis Assessment Review Team | View |
| None | Plaque Forming Unit | View |
| None | Physical Exam | View |
| None | Principal Investigator | View |
| None | Post Injection Reactogenicity | View |
| None | Project Manager | View |
| None | Prothrombin Time | View |
| None | Partial Thromboplastin Time | View |
| None | Particle Units | View |
| None | Ravn Virus | View |
| None | Recombinant Human Adenovirus Serotype 5 | View |
| None | Species Reston ebolavirus | View |
| None | Ribonucleic Acid | View |
| None | Rapid Plasma Regain | View |
| None | Reverse Transcription Polymerase Chain Reaction | View |
| None | Serious Adverse Event | View |
| None | Severe Acute Respiratory Syndrome Coronavirus 2 | View |
| None | Statistical Analysis System | View |
| None | Schedule of Events | View |
| None | Standard Operating Procedure | View |
| None | Serum Separator Tube | View |
| None | Species Sudan Ebolavirus | View |
| None | Suspected, Unexpected and Serious Adverse Reaction | View |
| None | Species Taï Forest Ebolavirus | View |
| None | Technical Resources International, Inc | View |
| None | Universal Donor History Questionnaire | View |
| None | Upper Limit of Normal | View |
| None | Viral Particles | View |
| None | Vaccine Research Center | View |
| None | Vesicular Stomatitis Virus | View |
| None | Variant Creutzfeldt-Jakob Disease | View |
| None | White blood cell | View |
| None | World Health Organization | View |
| None | Western Institutional Review Board | View |
| None | Wild type | View |
| None | Zaire Ebola virus | View |
| None | Acquired Angioedema | View |
| None | Program, Inc. | View |
| None | Human adenovirus Serotype 5 | View |
| None | Activities of Daily Living | View |
| None | Adverse Event | View |
| None | Acquired Immunodeficiency Syndrome | View |
| None | Alanine aminotransferase | View |
| None | Assessment of Understanding | View |
| None | Aspartate Aminotransferase | View |
| None | Biomedical Advanced Research and Development Authority | View |
| None | Species Bundibugyo ebolavirus | View |
| None | Blood Establishment Computer System | View |
| None | Blood Urea Nitrogen | View |
| None | Recombinant Chimpanzee Adenovirus Serotype 3 | View |
| None | Recombinant Chimpanzee Adenovirus | View |
| None | Recombinant Chimpanzee Adenovirus Serotype 63 | View |
| None | Complete blood count | View |
| None | Center for Disease Control and Prevention | View |
| None | Code of Federal Regulations | View |
| None | Confidence Interval | View |
| None | Centimeters | View |
| None | Type 3-Vectored Ebola virus Vaccine | View |
| None | Type 3-Vectored Ebola Sudan Vaccine | View |
| None | Type 3-Vectored Marburg Vaccine | View |